Js Capital Management buys $2,109,570 stake in The Medicines Company (MDCO)

The Medicines Company (MDCO) : Js Capital Management scooped up 2,000 additional shares in The Medicines Company during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 57,000 shares of The Medicines Company which is valued at $2,109,570.The Medicines Company makes up approximately 1.20% of Js Capital Management’s portfolio.

Other Hedge Funds, Including , Pointstate Capital Lp reduced its stake in MDCO by selling 722,000 shares or 72.06% in the most recent quarter. The Hedge Fund company now holds 280,000 shares of MDCO which is valued at $10,362,800. The Medicines Company makes up approx 0.26% of Pointstate Capital Lp’s portfolio.Dekabank Deutsche Girozentrale boosted its stake in MDCO in the latest quarter, The investment management firm added 39,900 additional shares and now holds a total of 72,600 shares of The Medicines Company which is valued at $2,805,264. The Medicines Company makes up approx 0.03% of Dekabank Deutsche Girozentrale’s portfolio.Strs Ohio boosted its stake in MDCO in the latest quarter, The investment management firm added 1,100 additional shares and now holds a total of 6,000 shares of The Medicines Company which is valued at $227,760.Gemmer Asset Management boosted its stake in MDCO in the latest quarter, The investment management firm added 60 additional shares and now holds a total of 133 shares of The Medicines Company which is valued at $4,683.

The Medicines Company closed down -0.2 points or -0.51% at $38.97 with 7,19,720 shares getting traded on Thursday. Post opening the session at $39, the shares hit an intraday low of $38.61 and an intraday high of $40 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, The Medicines Company reported $-0.62 EPS for the quarter, beating the analyst consensus estimate by $ 0.35 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $-0.97. The company had revenue of $54.73 million for the quarter, compared to analysts expectations of $42.26 million. The company’s revenue was down -26.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $-0.65 EPS.

The Medicines Company is a global biopharmaceutical company. The Company’s marketed products are: Angiomax (bivalirudin) Cleviprex (clevidipine) injectable emulsion Minocin (minocycline) for injection Orbactiv (oritavancin) PreveLeak and Recothrom Thrombin topical (Recombinant). The Company’s products in development include its registration stage product candidates and its research and development product candidates. It has a pipeline of acute and intensive care hospital products in development including four registration stage product candidates for which the Company has submitted applications for regulatory approval in the United States cangrelor IONSYS (fentanyl iontophoretic transdermal system) Raplixa formerly referred to as Fibrocaps and RPX-602. The Company’s four research and development product candidates include ABP-700 ALN-PCSsc Carbavance and MDCO-216. The Company also develops ABP-700 an intravenous anesthetic which is in Phase I of clinical studies.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *